OnTheIssuesLogo

Donna Edwards on Drugs

 

 


Rated B by NORML, indicating a pro-drug-reform stance.

Edwards scores B by the NORML on drug reform

OnTheIssues.org interprets the 2016 NORML scores as follows:

About NORML (from their website, www.norml.org):

National Organization for the Reform of Marijuana Law's mission is to move public opinion sufficiently to achieve the repeal of marijuana prohibition so that the responsible use of cannabis by adults is no longer subject to penalty.

NORML is a nonprofit, public-interest lobby that for more than 30 years has provided a voice for those Americans who oppose marijuana prohibition. We represent the interests of the tens of millions of Americans who smoke marijuana responsibly and believe the recreational and medicinal use of marijuana should no longer be a crime.

NORML supports the removal of all criminal penalties for the private possession & responsible use of marijuana by adults, including the cultivation for personal use, and the casual nonprofit transfers of small amounts. This model is called "decriminalization."

NORML additionally supports the development of a legally controlled market for marijuana, where consumers could purchase it from a safe, legal and regulated source. This model is referred to as "legalization."

NORML believes that marijuana smoking is not for kids and should only be used responsibly by adults. As with alcohol consumption, it must never be an excuse for misconduct or other bad behavior. Driving or operating heavy equipment while impaired from marijuana should be prohibited.

NORML strongly supports the right of patients to use marijuana as a medicine when their physician recommends it to relieve pain and suffering.

Lastly, NORML supports the right of farmers to commercially cultivate hemp for industrial purposes, such as food and fiber production.

Source: NORML website 16_NORML on Nov 8, 2016

Distribute sterile syringes to reduce AIDS and hepatitis.

Edwards signed Community AIDS and Hepatitis Prevention Act

To permit the use of Federal funds for syringe exchange programs for purposes of reducing the transmission of bloodborne pathogens, including HIV and viral hepatitis.

    Congress finds as follows:
  1. Each year, approximately 12,000 Americans contract HIV/AIDS and approximately 19,000 Americans contract the hepatitis C virus directly or indirectly from sharing contaminated syringes.
  2. A 2005 comprehensive international review of the evidence of the effectiveness of syringe exchange programs in preventing HIV transmission shows that such programs reduce HIV transmission and are cost-effective.
  3. Research has shown that injection drug users who are referred to addiction treatment from syringe exchange programs are more likely to enter and remain in treatment.
  4. Research has shown that, by providing safe disposal of used injection equipment, syringe exchange programs significantly reduce the number of improperly discarded syringes in the community, thereby reducing the exposure of police and others to dangers of blood-borne disease from accidental syringe sticks.
  5. Syringe exchange programs reduce the prevalence of HIV among injection drug users.
  6. Despite the scientific and public health consensus that syringe exchange programs reduce HIV and do not increase substance abuse, a ban on funding syringe exchange has been enacted as part of each Appropriations Act since 1998.
  7. The Public Health Service Act, as added by the Ryan White Comprehensive AIDS Resources Emergency Act of 1990, is subject to a statutory ban on funding needle exchange programs.
Notwithstanding any other provision of law, nothing shall prohibit the use of Federal funds to establish or carry out a program of distributing sterile syringes to reduce the transmission of bloodborne pathogens, including the human immunodeficiency virus (HIV) and viral hepatitis.
Source: HR 179 2009-H179 on Jan 6, 2009

Other candidates on Drugs: Donna Edwards on other issues:
MD Gubernatorial:
Alec Ross
Larry Hogan
Martin O`Malley
Richard Madaleno
Robert Ehrlich
MD Senatorial:
Benjamin Cardin

MD politicians
MD Archives

Retiring in 2014 election:
GA:Chambliss(R)
IA:Harkin(D)
MI:Levin(D)
MT:Baucus(D)
NE:Johanns(R)
SD:Johnson(D)
WV:Rockefeller(D)

Retired as of Jan. 2013:
AZ:Kyl(R)
CT:Lieberman(D)
HI:Akaka(D)
ND:Conrad(D)
NM:Bingaman(D)
TX:Hutchison(R)
VA:Webb(D)
WI:Kohl(D)
Senate races 2017-8:
AL: Strange(R) ; no opponent yet
AZ: Flake(R) vs. Ward(R)
CA: Feinstein(D) vs. Eisen(D) vs. Sanchez?(D) vs. Garcetti?(D)
CT: Murphy(D) ; no opponent yet
DE: Carper(D) vs. Biden?(D) vs. Markell?(D)
FL: Nelson(D) vs. DeSantis(R) vs. Jolly(R) vs. Lopez-Cantera(R)
HI: Hirono(D) ; no opponent yet
IN: Donnelly(D) vs. Hurt(R)
MA: Warren(D) vs. Ayyadurai(R)
MD: Cardin(D) ; no opponent yet
ME: King(I) vs. LePage?(R)
MI: Stabenow(D) vs. Bouchard?(R)
MN: Klobuchar(D) vs. Paulsen?(R)
MO: McCaskill(D) vs. Kinder?(R)
MS: Wicker(R) vs. McDaniel?(R)
MT: Tester(D) vs. Racicot?(R)

ND: Heitkamp(D) vs. Becker?(R)
NE: Fischer(R) ; no opponent yet
NJ: Menendez(D) vs. Chiesa(R) vs. Codey?(D) vs. Chiesa?(R)
NM: Heinrich(D) vs. Sanchez(R)
NV: Heller(R) vs. Sandoval?(R)
NY: Gillibrand(D) vs. Kennedy?(D)
OH: Brown(D) vs. Mandel(R)
PA: Casey(D) vs. Saccone(R)
RI: Whitehouse(D) ; no opponent yet
TN: Corker(R) vs. Crim(I)
TX: Cruz(R) vs. Bush?(R)
UT: Hatch(R) vs. McMullin?(R) vs. Romney?(R)
VT: Sanders(I) vs. Giordano(D)
VA: Kaine(D) vs. Cuccinelli?(R) vs. Fiorina?(R)
WA: Cantwell(D) ; no opponent yet
WV: Manchin(D) vs. Raese(R) vs. Goodwin?(R)
WI: Baldwin(D) vs. Grothman?(R) vs. Gallagher?(R)
WY: Barrasso(R) ; no opponent yet
Abortion
Budget/Economy
Civil Rights
Corporations
Crime
Drugs
Education
Energy/Oil
Environment
Families
Foreign Policy
Free Trade
Govt. Reform
Gun Control
Health Care
Homeland Security
Immigration
Jobs
Principles
Social Security
Tax Reform
Technology
War/Peace
Welfare

Other Senators
Senate Votes (analysis)
Bill Sponsorships
Affiliations
Policy Reports
Group Ratings

Contact info:
Fax Number:
202-225-8714
Mailing Address:
Cannon HOB 318, Washington, DC 20515
Phone number:
(202) 225-8699





Page last updated: Aug 25, 2017